Relay Therapeuti
Stock
Stock
Ticker: RLAY
RLAY
Price
Price
CHART BY
Frequently asked questions
What is Relay Therapeuti's market capitalization?
The market capitalization of Relay Therapeuti is $4.03B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Relay Therapeuti?
Relay Therapeuti's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.567. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Relay Therapeuti's stock?
Currently, 13 analysts cover Relay Therapeuti's stock, with a consensus target price of $27.58. Analyst ratings provide insights into the stock's expected performance.
What is Relay Therapeuti's revenue over the trailing twelve months?
Over the trailing twelve months, Relay Therapeuti reported a revenue of $10.35M.
What is the EBITDA for Relay Therapeuti?
Relay Therapeuti's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$308.22M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Relay Therapeuti?
Relay Therapeuti has a free cash flow of -$212.20M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Relay Therapeuti have, and what sector and industry does it belong to?
Relay Therapeuti employs approximately 192 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Relay Therapeuti's shares?
The free float of Relay Therapeuti is 171.66M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.03B
- EPS (TTM)
- -$1.567
- Free Float
- 171.66M
- Revenue (TTM)
- $10.35M
- EBITDA (TTM)
- -$308.22M
- Free Cashflow (TTM)
- -$212.20M
Pricing
- 52W span
- $5.95$21.23
Analyst Ratings
The price target is $27.58 and the stock is covered by 13 analysts.
Buy
13
Hold
0
Sell
0
Information
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
- Employees
- 192
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- RLAY
Fundamentals & EOD data from FactSet